



Patient Support Services

The single point of engagement for PYRUKYND[®]
prescription and access support.

Visit PYRUKYND.myAgios.com/hcp or call 1-800-951-3889.



INDICATION

PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Please see Important Safety Information throughout and full Prescribing Information for PYRUKYND in pocket.

FOR ADULT PATIENTS WITH PK DEFICIENCY

myAgios® Patient Support Services: Single point of engagement for prescription and access support

Centralized enrollment for eligible patients, including prescription fulfillment, financial assistance, access, and adherence support



ACCESS AND BENEFITS INVESTIGATION SERVICES

- Support with insurance coverage
- Administer patient assistance programs



PRESCRIPTION FULFILLMENT THROUGH EXCLUSIVE SPECIALTY PHARMACY

- Commercial product dispensing
- Guidance with dosing questions and coordination of refills



DEDICATED AND CLINICALLY EXPERIENCED PATIENT SUPPORT MANAGERS (PSMs) CAN OFFER:

- Single point of contact for HCPs and office staff to help patients access program offerings
- Educational resources and information about financial assistance

IMPORTANT SAFETY INFORMATION

Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Adverse Reactions: Serious adverse reactions occurred in 10% of patients receiving PYRUKYND in the ACTIVATE trial, including atrial fibrillation, gastroenteritis, rib fracture, and musculoskeletal pain, each of which occurred in 1 patient. In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities ($\geq 10\%$) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.



Prescribe PYRUKYND® in 3 steps

- 1** Download and fill out the PYRUKYND Enrollment Form at PYRUKYND.myAgios.com/hcp/enrollment.
- 2** Fax the form to myAgios at **1-800-951-7814**. Call a PSM at **1-800-951-3889** with any questions.
- 3** A dedicated myAgios Patient Support Manager will reach out to office staff and patients directly to provide support throughout the treatment process.

Financial assistance options and coverage support

myAgiOS can connect patients to financial assistance and coverage support programs to help with access to PYRUKYND, including information about:



THE PYRUKYND COPAY PROGRAM

- This program lowers costs for eligible patients to \$0 per prescription if their copay exceeds that amount
- Patients participating in government healthcare insurance are not eligible



THE PATIENT ASSISTANCE PROGRAM

- Offers free prescriptions to eligible uninsured and underinsured patients



COVERAGE INTERRUPTION

- This program is for eligible commercially insured patients who have filled at least one previous prescription of PYRUKYND and who experience a temporary loss or change in coverage
- Free 28-day prescription (with up to 2 refills) for eligible commercially insured patients experiencing a temporary loss or gap in coverage
- Patients participating in government healthcare insurance are not eligible

Other forms of assistance may be available, including assistance from independent foundations for patients with government and commercial insurance. myAgiOS can provide a referral to one of these foundations. Eligibility is determined by the individual foundation. Agios is not affiliated with these organizations.

This program is not intended as medical advice and patients should consult their healthcare team with questions related to their treatment.

IMPORTANT SAFETY INFORMATION (cont.)

Drug Interactions:

- Strong CYP3A Inhibitors and Inducers: Avoid concomitant use
- Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily
- Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage
- Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index
- UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index
- P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index

Please see additional Important Safety Information throughout and full Prescribing Information for PYRUKYND in pocket.



Agios' experienced and dedicated Patient Support Managers can offer assistance for patients



Nefar Moran
Patient Support Manager
Cambridge, MA

Elisabeth Herdic
Patient Support Manager
Cambridge, MA

myAgios® Patient Support Managers:

- Have over 30 years of collective experience and experience with rare diseases
- Tailor the support experience for patients and their caregivers based upon their unique needs in living with PK deficiency
- Can direct patients to PYRUKYND® and PK deficiency educational resources, including community connections
- Help patients navigate financial assistance questions and eligibility criteria
- Can be a supportive resource and provide adherence support through
 - Social support via patient webinars with other PK deficiency patients and caregivers
 - Regular phone calls (cadence is approximately monthly)
 - Email communications

When a patient is prescribed PYRUKYND and the enrollment form is faxed to myAgios, the process for support can begin. HIPAA consent must be obtained to complete enrollment into the myAgios program.



Connect patients with a dedicated Patient Support Manager to ask questions.

Call **1-800-951-3889**, Mon-Fri, 8 AM to 6 PM ET or visit **PYRUKYND.myAgios.com/hcp** to learn more.

IMPORTANT SAFETY INFORMATION (cont.)

Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

Please see additional Important Safety Information throughout and full Prescribing Information for PYRUKYND in pocket.



myAgios is a registered trademark of Agios Pharmaceuticals, Inc.
©2022 Agios Pharmaceuticals, Inc. All rights reserved. PYR-US-0013 2/22

